Innocuité et efficacité du bimekizumab chez les patients atteints de spondylarthrite ankylosante active : Résultats à trois ans d'un essai contrôlé randomisé de phase IIb et de son étude de prolongation ouverte
Expert Opin Biol Ther. 2023 doi: 10.1080/14712598.2022.2156283
This review aimed to discuss the emerging agents for the treatment of axSpA.
It details safety data on filgotinib, highlighting that sperm toxicity does not appear to be a concern. It was concluded that combining agents targeting TNFa and IL-187 and/or JAK needs further investigation and may hold the key to assisting the large body of patients with inflammatory rheumatic conditions not achieving remission
Keywords:
